Georgios Skretas

Dr. Georgios Skretas


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2011 in Microbial Cell Factories
Verified
Journal Article
Open access
PDF file
TMTomohiro Makino
Tomohiro Makino
GSGeorgios Skretas
Georgios Skretas
GGGeorge Georgiou
George Georgiou
Protein expression in Escherichia coli represents the most facile approach for the preparation of non-glycosylated proteins for analytical and preparative purposes. So far, the optimization of recombinant expression has largely remained a matter of trial and error and has relied upon varying parameters, such as expression vector, media composition, growth temperature and chaperone co-expression. Recently several new approaches for the genome-scale engineering of E. coli to enhance recombinant protein expression have been developed. These methodologies now enable the generation of optimized E. coli expression strains in a manner analogous to metabolic engineering for the synthesis of low-molecular-weight compounds. In this review, we provide an overview of strain engineering approaches useful for enhancing the expression of hard-to-produce proteins, including heterologous membrane proteins.

1 February 2005 in Protein Science
Verified
Journal Article
Closed access
PDF file
GSGeorgios Skretas
Georgios Skretas
DWDavid W. Wood
David W. Wood

24 May 2024 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
MTMaria Tsekrekou
Maria Tsekrekou
MGMaria Giannakou
Maria Giannakou
KPKaterina Papanikolopoulou
Katerina Papanikolopoulou
GSGeorgios Skretas
Georgios Skretas
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with severe socio-economic impact. A hallmark of ALS pathology is the presence of aberrant cytoplasmic inclusions composed of misfolded and aggregated proteins, including both wild-type and mutant forms. This review highlights the critical role of misfolded protein species in ALS pathogenesis, particularly focusing on Cu/Zn superoxide dismutase (SOD1) and TAR DNA-binding protein 43 (TDP-43), and emphasizes the urgent need for innovative therapeutic strategies targeting these misfolded proteins directly. Despite significant advancements in understanding ALS mechanisms, the disease remains incurable, with current treatments offering limited clinical benefits. Through a comprehensive analysis, the review focuses on the direct modulation of the misfolded proteins and presents recent discoveries in small molecules and peptides that inhibit SOD1 and TDP-43 aggregation, underscoring their potential as effective treatments to modify disease progression and improve clinical outcomes.

7 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DZDimitra Zarafeta
Dimitra Zarafeta
DKDimitrios Kissas
Dimitrios Kissas
CSChristopher Sayer
Christopher Sayer
SGSóley R Gudbergsdottir
Sóley R Gudbergsdottir
ELEfthymios Ladoukakis
Efthymios Ladoukakis
FKFragiskos N. Kolisis
Fragiskos N. Kolisis
With the ultimate goal of identifying robust cellulases for industrial biocatalytic conversions, we have isolated and characterized a new thermostable and very halotolerant GH5 cellulase. This new enzyme, termed CelDZ1, was identified by bioinformatic analysis from the genome of a polysaccharide-enrichment culture isolate, initiated from material collected from an Icelandic hot spring. Biochemical characterization of CelDZ1 revealed that it is a glycoside hydrolase with optimal activity at 70°C and pH 5.0 that exhibits good thermostability, high halotolerance at near-saturating salt concentrations, and resistance towards metal ions and other denaturing agents. X-ray crystallography of the new enzyme showed that CelDZ1 is the first reported cellulase structure that lacks the defined sugar-binding 2 subsite and revealed structural features which provide potential explanations of its biochemical characteristics.

19 December 2016 in Scientific Reports
Verified
Journal Article
Open access
DZDimitra Zarafeta
Dimitra Zarafeta
DMDanai Moschidi
Danai Moschidi
ELEfthymios Ladoukakis
Efthymios Ladoukakis
SGSergey Gavrilov
Sergey Gavrilov
Evangelia ChrysinaEvangelia Chrysina
Evangelia Chrysina
FKFragiskos N. Kolisis
Fragiskos N. Kolisis
Biocatalysts exerting activity against ester bonds have a broad range of applications in modern biotechnology. Here, we have identified a new esterolytic enzyme by screening a metagenomic sample collected from a hot spring in Kamchatka, Russia. Biochemical characterization of the new esterase, termed EstDZ2, revealed that it is highly active against medium chain fatty acid esters at temperatures between 25 and 60 °C and at pH values 7–8. The new enzyme is moderately thermostable with a half-life of more than six hours at 60 °C, but exhibits exquisite stability against high concentrations of organic solvents. Phylogenetic analysis indicated that EstDZ2 is likely an Acetothermia enzyme that belongs to a new family of bacterial esterases, for which we propose the index XV. One distinctive feature of this new family, is the presence of a conserved GHSAG catalytic motif. Multiple sequence alignment, coupled with computational modelling of the three-dimensional structure of EstDZ2, revealed that the enzyme lacks the largest part of the “cap” domain, whose extended structure is characteristic for the closely related Family IV esterases. Thus, EstDZ2 appears to be distinct from known related esterolytic enzymes, both in terms of sequence characteristics, as well as in terms of three-dimensional structure.

1 March 2011 in Metabolic Engineering
Verified
Journal Article
Closed access
TMTomohiro Makino
Tomohiro Makino
GSGeorgios Skretas
Georgios Skretas
TKTae-Hyun Kang
Tae-Hyun Kang
GGGeorge Georgiou
George Georgiou